STRM.BIO raised $8 million to advance its non-viral, cell-derived megakaryocyte vesicle delivery platform for in vivo genetic medicines, targeting rare hematologic diseases such as Fanconi anemia and CAR-T–based therapies.
STRM.BIO raised $8 million to advance its non-viral, cell-derived megakaryocyte vesicle delivery platform for in vivo genetic medicines, targeting rare hematologic diseases such as Fanconi anemia and CAR-T–based therapies.